Corcept Therapeutics Incorporated reported preliminary financial results for the fourth quarter and full year ended December 31, 2015. Corcept reported preliminary revenue of $15.0 million for the fourth quarter of 2015, a 66% increase from the fourth quarter of 2014. Preliminary GAAP net income for the fourth quarter of 2015 was $0.01 per share, compared to a net loss of $0.04 per share in the fourth quarter of 2014.

Corcept reported preliminary revenue of $50.3 million for the full year 2015, an 89% increase from 2014. For the full year, the company reported a preliminary GAAP net loss of $0.06 per share for 2015, compared to a net loss of $0.31 per share in 2014.

The company provided 2016 revenue guidance. 2016 revenue guidance in between $76 million to $81 million.